Adverse effects and other safety aspects of the hepatitis C antivirals

Journal of Gastroenterology and Hepatology (Australia)

Volumn 15, Issue SUPPL. MAY, 2000, Pages

  Chutaputti, Anuchit ^a  

^a PRAMONGKUTKLAO HOSPITAL   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN;

AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EYE DISEASE; HEPATITIS C; HUMAN; LIVER TOXICITY; LUNG TOXICITY; MENTAL DISEASE; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; RETREATMENT; SKIN DISEASE; TERATOGENICITY; THYROID DISEASE;

EID: 0033919083     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2000.02114.x     Document Type: Conference Paper

References (89)

1. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26 (Suppl. 1): S112-21.
2. Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin. Liver Dis. 1989; 9: 273-7.
3. Fattovich G, Giustina G, Favarato S et al. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon. J. Hepatol. 1996; 24: 38-47.
4. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N. Engl. J. Med. 1989; 321: 1501-6.
5. Michael FW, Hoofnagle JH. Therapy of hepatitis C. Semin. Liver Dis. 1995; 15: 82-90.
6. De Salvo L, Plumacher Z, Gomez O et al. Hypertriglyceridemia following treatment with interferon alpha in essential thrombocythemia. Invest. Clin. 1996; 37: 177-81.
7. Ruiz-Moreno M, Carreno V, Rua MJ et al. Increase in triglycerides during alpha-interferon treatment of chronic viral hepatitis (Letter). J. Hepatol. 1992; 16: 384.
8. Berruti A, Gorzegno G, Vitetta G et al. Hypertriglyceridemia during long-term interferon-alpha therapy: efficacy of diet and gemfibrosil treatment: a case report. Tumori 1992; 78: 353-5.
9. Bory E, Garcia Rico A, Pedro-Botet J et al. Severe hypertriglyceridemia during the course of treatment with interferon-alpha in a patient with chronic hepatitis C (Letter). Gastroenterol. Hepatol. 1996; 19: 542.
10. Okanoue T, Sakamoto S, Itoh Y et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J. Hepatol. 1996; 25: 283-91.
11. Tada H, Saitoh S, Nagakawa Y et al. Ischemic colitis during interferon-alpha treatment for chronic active hepatitis C. J. Gastroenterol. 1996; 31: 582-4.
12. Renault PF, Hoofnagle JH, Park Y et al. Psychiatric complications of long-term interferon alfa therapy. Arch. Intern. Med. 1987; 147: 1577-80.
13. La Civita L, Zignego AL, Lombardini F et al. Exacerbation of peripheral neuropathy during alpha-interferon therapy in a patient with mixed cryoglobulinemia and hepatitis B virus infection. J. Rheumatol. 1996; 23: 1641-3.
14. Konishi T. A case of myasthenia gravis which developed myasthenic crisis after alpha-interferon therapy for chronic hepatitis C. Rinsho Shinkeigaku (Clin. Neurol.) 1996; 36: 980-5.
15. Merimsky O, Chaitchik S. Neurotoxicity of interferon-alpha. Anti-Cancer Drugs 1992; 3: 567-70.
16. Merimsky O, Nisipeanu P, Loewenstein A et al. Interferon-related cortical blindness. Cancer Chemother. Pharmacol. 1992; 29: 329-30.
17. Shakil AO, Di Bisceglie AM, Hoofnagle JH. Seizures during alpha interferon therapy. J. Hepatol. 1996; 24: 48-51.
18. Janssen HLA, Berk L, Vermeulen M et al. Seizures associated with low-dose α-interferon (Letter). Lancet 1990; 336: 1580.
19. Perrillo R, Tamburro C, Regenstein F et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995; 109: 908-16.
20. Hoofnagle JH, Di Bisceglie AM, Waggoner JG et al. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993; 104: 1116-21.
21. Janssen HL, Brouwer JT, Nevens F et al. Fatal hepatic decompensation associated with interferon alfa: European concerted action on viral hepatitis (Eurohep). BMJ 1993; 306: 107-8.
22. Vento S, Di Perri G, Garofano T et al. Hazards of interferon therapy for HBV-seronegative chronic hepatitis (Letter). Lancet 1989; 2: 926.
23. Garcia-Buey L, Garcia-Monzon C, Rodriguez S et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995; 108: 1770-7.
24. Todros L, Saracco G, Durazzo M et al. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver kidney microsomes. Hepatology 1995; 22: 1374-8.
25. Farhat BA, Johnson PJ, Williams R. Hazards of interferon treatment in patients with autoimmune chronic active hepatitis. J. Hepatol. 1994; 20: 560-1.
26. Heathcote EJ. Autoimmune hepatitis and chronic hepatitis C: latent or initiated by interferon therapy. Gastroenterology 1995; 108: 1942-4.
27. Cianciara J, Laskus T. Development of transient autoimmune hepatitis during interferon treatment of chronic hepatitis B. Dig. Dis. Sci. 1995; 40: 1842-4.
28. Ruiz-Moreno M, Rua MJ, Carreno V et al. Autoimmune chronic hepatitis type 2 manifested during interferon therapy in children (Letter). J. Hepatol. 1991; 12: 165-6.
29. Noda K, Enomoto N, Arai K et al. Induction of antinuclear antibody after interferon therapy in patients with type-C chronic hepatitis: its relation to the efficacy of therapy. Scand. J. Gastroenterol. 1996; 31: 716-22.
30. Mayet WJ, Hess G, Garken G et al. Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 1989; 10: 24-8.
31. Fonseca V, Thomas M, Dusheiko G. Thyrotropin receptor antibodies following treatment with recombinant alpha-interferon in patients with hepatitis. Acta Endocrinol. 1991; 125: 491-3.
32. Preziati D, La Rosa L, Covini G et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur. J. Endocrinol. 1995; 132: 587-93.
33. Carella C, Amato G, Biondi B et al. Longitudinal study of antibodies against thyroid in patients undergoing interferon-α therapy for HCV chronic hepatitis. Horm. Res. 1995; 44: 110-4.
34. Marcellin P, Pouteau M, Renard P et al. Sustained hypothyroidism induced by recombinant a interferon in patients with chronic hepatitis C. Gut 1992; 33: 855-6.
35. Lisker-Mekman M, Di Bisceglie AM, Usala SJ et al. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992; 102: 2155-60.
36. Regulatory Affairs. Study Monitoring Data. Thousand Oaks, CA: Amgen, 1997.
37. Watanabe U, Hashimoto E, Hisamitsu T et al. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am. J. Gastroenterol. 1994; 89: 399-403.
38. Chung YW, Shong YK. Development of thyroid autoimmunity after administration of recombinant human interferon-alpha 2b for chronic viral hepatitis. Am. J. Gastroenterol. 1993; 88: 244-7.
39. Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-α therapy. Clin. Endocrinol. 1996; 44: 635-42.
40. Baudin E, Marcellin P, Pouteau M et al. Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin. Endocrinol. 1993; 39: 657-61.
41. Barbolla L, Paniagua C, Outeirino J et al. Haemolytic anaemia to the alpha-interferon treatment: a proposed mechanism. Vox Sang. 1993; 65: 156-7.
42. Yanaihara H, Nakazono M, Tsunoda S. A case of drug-induced immune hemolytic anemia during alpha-interferon therapy for renal cell carcinoma. Nippon Hinyokika Gakkai Zasshi (Jpn J. Urol.) 1996; 87: 714-17 (in Japanese).
43. Stern SC, Asagba GO, Hegde UM. Prolonged thrombocytopenia following alpha-interferon for refractory immune thrombocytopenic purpura. Clin. Lab. Haematol. 1994; 16: 183-5.
44. Cavanna L, Vallisa D, Berte R et al. Severe immune thrombocytopenic purpura relapse after alpha-interferon in chronic myeloid leukemia, successfully treated with cyclosporine (Letter). Am. J. Hematol. 1994; 47: 255-6.
45. Mehta ND, Hooberman AL, Vokes EE et al. A 35-year-old patient with chronic myelogenous leukemia developing systemic lupus erythematosus after alpha-interferon therapy (Letter). Am. J. Hematol. 1992; 41: 141.
46. Schilling PJ, Kurzrock R, Kantarjian H et al. Development of systemic lupus erythematosus after interferon therapy for chronic myologenous leukemia. Cancer 1991; 68: 1536-7.
47. Tolaymat A, Leventhal B, Sakarcan A et al. Systemic lupus erythematosus in a child receiving long-term interferon therapy. J. Pediatr. 1992; 120: 429-32.
48. Waguri M, Hanafusa T, Itoh N et al. Occurrence of IDDM during interferon therapy for chronic viral hepatitis. Diabetes Res. Clin. Pract. 1994; 23: 33-6.
49. Fabris P, Betterle C, Floreani A et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis (Letter). Lancet 1992; 340: 548.
50. Foulis AK. Interferon-alpha and IDDM (Letter & Comment). Diabetologia 1996; 39: 127.
51. 2b therapy for chronic active hepatitis C. Dig. Dis. Sci. 1995; 40: 1226-30.
52. Noda K, Enomoto N, Aria K et al. Induction of antinuclear antibody after interferon therapy in patients with type-C chronic hepatitis: its relation to the efficacy of therapy. Scand. J. Gastroenterol. 1996; 31: 716-22.
53. Di Cesare E, Previti M, Russo F et al. Interferon-α therapy may induce insulin autoantibody development in patients with chronic viral hepatitis. Dig. Dis. Sci. 1996; 41: 1672-7.
54. Imagawa I, Itoh N, Hanafusa T et al. Autoimmune endocrine disease induced by recombinant interferon-α therapy for chronic active type C hepatitis. J. Clin. Endocrinol. Metab. 1995; 80: 922-6.
55. Coroneos E, Truong L, Olivero J. Fibrillary glomerulonephritis associated with hepatitis C viral infection. Am. J. Kidney Dis. 1997; 29: 132-5.
56. Coroneos E, Petrusevska G, Varghese F et al. Focal segmental glomerulosclerosis with acute renal failure associated with alpha-interferon therapy. Am. J. Kidney Dis. 1996; 28: 888-92.
57. Pol S, Thiers V, Carnot F et al. Efficacy and tolerance of α-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int. 1995; 47: 1412-18.
58. Teragawa H, Hondo T, Amano H et al. Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. Jpn Heart J. 1996; 37: 905-15.
59. Sartori M, Andorno S, La Terra G et al. Assessment of interferon cardiotoxicity with quantitative radionuclide angiocardiography. Eur. J. Clin. Invest. 1995; 25: 68-70.
60. Simsek H, Savas C, Akkiz H et al. Interferon-induced vitiligo in a patients with chronic viral hepatitis C infection. Dermatology 1996; 193: 65-6.
61. Bernstein D, Reddy KR, Jeffers L et al. Canities and vitiligo complicating interferon therapy for hepatitis C. Am. J. Gastroenterol. 1995; 90: 1176-7.
62. Areias J, Velho GC, Cerqueira R et al. Lichen planus and chronic hepatitis C: exacerbation of the lichen under interferon-alpha-2a therapy. Eur. J. Gastroenterol. Hepatol. 1996; 8: 825-8.
63. Protzer U, Ochsendorf FR, Leopolder-Ochsendorf A et al. Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C. Gastroenterology 1993; 104: 903-5.
64. Funk J, Langeland T, Schrumpf E et al. Psoriasis induced by interferon-alpha. Br. J. Dermatol. 1991; 125: 463-5.
65. Makino Y, Tanaka H, Nakamura K et al. Arthritis in a patient with psoriasis after interferon-alpha therapy for chronic hepatitis C. J. Rheumatol. 1994; 21: 1771-2.
66. Lombardini F, Taglione E, Riente L et al. Psoriatic arthritis with spinal involvement in a patient receiving alpha-interferon for chronic hepatitis C. Scand. J. Rheumatol. 1997; 26: 58-60.
67. Georgetson MJ, Yarze JC, Lalos AT et al. Exacerbation of psoriasis due to interferon-a treatment of chronic active hepatitis. Am. J. Gastroenterol. 1993; 88: 1756-8.
68. Kawano T, Shigehira M, Uto H et al. Retinal complications during interferon therapy for chronic hepatitis C. Am. J. Gastroenterol. 1996; 91: 309-13.
69. Purvin VA. Anterior ischemic optic neuropathy secondary to interferon alfa. Arch. Ophthalmol 1995; 113: 1041-4.
70. Kanda Y, Shigeno K, Kinoshita N et al. Sudden hearing loss associated with interferon. Lancet 1994; 343: 1134-5.
71. Chin K, Tabata C, Satake N et al. Pneumonitis associated with natural and recombinant interferon alfa therapy for chronic hepatitis C. Chest 1994; 105: 939-41.
72. Yufu Y, Yamashita S, Nishimura J et al. Interstitial pneumonia caused by interferon-alpha in chronic myelogenous leukemia (Letter). Am. J. Hematol. 1994; 47: 253.
73. Hizawa N, Kojima J, Kojima T et al. A patient with chronic hepatitis C who simultaneously developed interstitial pneumonia, hemolytic anemia and cholestatic liver dysfunction after alpha-interferon administration. Intern. Med. 1994; 33: 337-41.
74. Xu Z-X, Hoffman J, Patel I, Joubert P. Single-dose/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon and interferon alfa-2a to healthy subjects. Hepatology 1998; 28: 702A.
75. Patterson JL, Fernandez-Larson R. Molecular action of ribavirin. Rev. Infect. Dis. 1990; 12: 1132-46.
76. Bodenheimer HC Jr, Linsay KL, Davis GL et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26: 473-7.
77. McHutchison JG, Poynard T. Combination therapy with interferon alfa and ribavirin as retreatment of chronic hepatitis C. Semin. Liver Dis. 1999; 19 (Suppl. 1): 57-65.
78. Poynard T, Marcellin P, Lee S et al. An international randomized trial of interferon alfa-2b and ribavirin (intron A/rebetol) 48 or 24 weeks vs intron A 48 weeks for first line treatment of chronic hepatitis C. Hepatology 1998; 28: 387A.
79. McHutchison J, Gordon S, Schiff E et al. Interferon alfa 2b alone or in combination with ribavirin in naïve chronic HCV patients: a US multicenter trial. Hepatology 1998; 28: 387A.
80. Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N. Engl. J. Med. 1998; 339: 1493-9.
81. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 1998; 339: 1485-92.
82. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32.
83. Barbaro G, Lorenzo G, Soldini M et al. Interferon alfa-2b and ribavirin in combination for chronic hepatitis C patients not responding to interferon alfa alone: an Italian multicenter, randomized, controlled, clinical study, Am. J. Gastroenterol. 1998; 93: 2445-51.
84. Schalm SW, Hansen BE, Chemello L et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: Meta-analysis of individual patient data from European centers. J. Hepatol. 1997; 26: 961-6.
85. Reichard O, Norkrans G, Fryden A et al. Randomised, double-blind, placebo-controlled trial of interferonα-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-7.
86. Reichard O, Norkrans G, Fryden A et al. Adding ribavirin to interferon alfa-2b for chronic hepatitis C infection increased virological response and nausea. Gut 1998; 43: 602.
87. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naïve patients. Semin. Liver Dis. 1999; 19 (Suppl. 1): 67-75.
88. Deep LS, Khouri AS, Hall CE et al. Interferon and ribavirin associated retinopathy in patients with hepatitis C. Hepatology 1998; 28: 371A.
89. EASL. International Consensus Conference on Hepatitis C. J. Hepatol. 1999; 30: 956-61.